OCTAVE, Ranibizumab in neovascular age-related macular degeneration

• Research type

  Research Study

• Full title

  A 24-month, phase IIIb, randomized, double-masked, multicenter study assessing the efficacy and safety of two treatment regimens of 0.5 mg ranibizumab intravitreal injections guided by functional and/or anatomical criteria, in patients with neovascular age-related macular degeneration (OCTAVE)

• IRAS ID

  123360

• Contact name

  James Warburton

• Contact email

  james.warburton@novartis.com

• Sponsor organisation

  Novartis Pharmaceuticals UK

• Eudract number

  2011-004959-39

• Clinicaltrials.gov Identifier

  NCT01780935

• REC name

  London - South East Research Ethics Committee

• REC reference

  13/LO/0520

• Date of REC Opinion

  20 May 2013

• REC opinion

  Further Information Favourable Opinion